The development of chronic kidney disease (CKD) is associated with poor outcomes largely due an increased likelihood of adverse cardiovascular events. Many factors are playing a role in cardiovascular disease in CKD including the development of vascular calcification (VC). Studies have indeed shown that the presence of VC is associated with decreased survival among patients with CKD. The pathogenesis of VC is itself multi-factorial. Likely playing a significant role is the altered mineral metabolism of CKD. Management of the altered mineral metabolism in CKD is quite difficult and may also play a role in the pathogenesis of VC. In this manuscript, we will review the pathogenesis of the altered mineral metabolism of CKD, its management, and how both may play a role in the development of VC.
Introduction
The prevalence of chronic kidney disease (CKD) is increasing, now affecting roughly 17% of the US population aged > 20 years [CDC, 2007] . Common conditions associated with CKD include type 2 diabetes mellitus, hypertension, and vascular disease, all of which have significant effects on overall health and survival. However, even after adjusting for the presence of such co-morbidities, CKD remains an independent risk factor for poor health outcomes [Go et al. 2004; Rahman et al. 2006 ]. Furthermore, as the severity of CKD increases, the risk for these adverse events also increases. Therefore, it is clear that CKD is a significant health concern in the US, and the rest of the world.
One of the adverse outcomes associated with CKD is the development of cardiovascular disease (CVD), which is the most common cause of death in these patients [Sarnak et al. 2003 ]. Among patients with advanced CKD treated with dialysis, the risk of death from CVD is 10-30 times greater than the general population [Sarnak et al. 2003 ]. While many factors are likely contributing to this increased CVD risk, recent evidence has suggested that the altered mineral metabolism seen in CKD may be playing an important role in consequent CVD. Altered mineral metabolism Correspondence to: [Davies et al. 2001] . Studies have suggested that the presence of VC, or one of its surrogate markers, is associated with increased CVD risk and poor outcomes among patients with advanced CKD [Okuno et al. 2007; Blacher et al. 2003 ].
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In the last decade, considerable progress has been made in understanding the pathogenesis of VC, particularly its relationship to the altered mineral metabolism seen in CKD. In this review, we will explore some of these recent advancements and examine the impact that altered mineral metabolism has on patients with CKD.
The altered mineral metabolism of CKD
The most important factors involved in the development of sHPT in CKD is phosphorous retention, low levels of 1,25-hydroxyvitamin D3 (1,25-OH 2 D3), and hypocalcemia [Davies et al. 2001; Slatopolsky et al. 1996; Slatopolsky et al. 1968] . With reduced nephron mass, maintenance of normal phosphorus balance requires increased phosphorus excretion per nephron to match intake of dietary phosphorus [Slatopolsky et al. 1968 ]. This occurs primarily via decreased tubular phosphorus reabsorption through enhanced secretion of parathyroid hormone (PTH) [Slatopolsky et al. 1996] and other circulating phosphaturic factors called phosphatonins [Gutierrez et al. 2005 ]. Phosphatonins, similar to PTH, block the tubular reabsorption of phosphorus. Probably the best studied of the phosphatonins in CKD is fibroblast growth factor -23 (FGF-23). In early stages of CKD, both PTH and FGF-23 levels are elevated prior to the development of hyperphosphatemia and are associated with decreased tubular reabsorption of phosphorus (increased fractional excretion) [Gutierrez et al. 2005 ]. These findings suggest that PTH and FGF-23 serve to maintain serum phosphorus in the normal range in the early stages of CKD. However, as glomerular filtration rate declines further, this compensatory mechanism is no longer sufficient and hyperphosphatemia develops.
The main natural supply of vitamin D depends on sun exposure and conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin. In the liver, vitamin D3 is converted to 25-hydroxyvitamin D3 (25-OH 2 D3) by the enzyme 25-hydroxylase. The active form of vitamin D, 1,25-hydroxyvitamin D3 (1,25-OH 2 D3) or calcitriol, is then formed in the kidney by the enzyme 1-alpha-hydroxylase. In severe CKD, renal expression of 1-alphahydroxylase is reduced [Satomura et al. 1988] leading to decreased levels of 1,25-OH 2 D3. In addition, both hyperphosphatemia [Tanaka et al. 1973] and elevated FGF-23 [Shimada et al. 2004 ] levels also suppress the 1-alpha hydroxylase enzyme. Among patients with CKD, significant negative correlations have been described between 1,25-OH 2 D3 levels and serum phosphorus and FGF-23 [Gutierrez et al. 2005 ]. Low levels of 1,25-OH 2 D3 contribute to the development of secondary hyperparathyroidism through decreased suppression of PTH secretion.
Finally, both the hyperphosphatemia and low levels of vitamin D contribute to the development of hypocalcemia. When elevated, phosphate complexes serum calcium leading to decreased ionized calcium. Low vitamin D lead to decreased intestinal absorption of calcium. The hypocalcemia that ensues further promotes the development of secondary hyperparathyroidism through decreased suppression of PTH secretion. Clearly, the development of sHPT in CKD is a complex process involving alterations in the normal homeostasis of calcium, phosphorous, and vitamin D. This process is maladaptive leading to significant skeletal and cardiovascular abnormalities. Management is subsequently based around dietary phosphorous restriction, dietary phosphorus binders, calcium supplementation, and vitamin D repletion.
Impact of the altered mineral metabolism in CKD
Several studies have suggested that markers of altered mineral metabolism, such as hyperphosphatemia, hypercalcemia, and elevated parathyroid hormone level are associated with poor outcomes. This was examined in the Dialysis Outcomes and Practice Patterns Study (DOPPS), a multicenter (North America, Europe, and Asia) observational study of dialysis practices and outcomes [Young et al. 2005 ]. The investigators found that for each 1 mg/dL increase in serum phosphorus, the relative risk for all-cause and CVD death was 4% and 9% respectively. For serum calcium, the relative risk increased by 10% and 14% respectively for each 1 mg/dL increase. The presence of sHPT also appeared to predict poor outcomes. For each 100 pg/mL increase in serum PTH, the relative risk for all-cause and CVD death increased by 1% and 2% respectively.
The association between phosphorus (or phosphate) and CVD event has also been examined among patients not on dialysis with or without CKD. Tonelli and colleagues [Tonelli et al. 2005] re-examined the patients in the Cholesterol and Recurrent Events trial in regards to outcomes as related to serum phosphate at baseline. Patients enrolled in this study had a history of hyperlipidemia and previous myocardial infarction. They found that for each 1 mg/dL increase in serum phosphate, the relative risk of death increased by 27%, even after adjusting for renal function. The results were similar even if investigators excluded patients with GFR <60 ml/min/1.73m 2 . Higher levels of serum phosphate were also associated with increased risk of new heart failure, myocardial infarction, and the composite endpoint of coronary death or nonfatal myocardial infarction, but not the risk of stroke [Tonelli et al. 2005 ].
While sHPT is associated with poor outcomes in dialysis patients, some investigators have also Review found that relative hypoparathyroidism may also be associated with increased mortality [Avram et al. 1996; Guh et al. 2002] . Here patients have normal or near-normal serum PTH levels often associated with elevated calcium levels. The low PTH levels in these patients could be due to overly aggressive treatment of sHPT with calcium and vitamin D, thus producing the hypercalcemia. However, low bone turnover is also associated with relative hypoparathyroidism [Lafage-Proust et al. 1999; Malluche et al. 2004] .
Here skeletal remodeling is markedly reduced leading to a decreased skeletal "buffering" of exogenous calcium intake [Lafage-Proust et al. 1999; Kurz et al. 1994 ]. In such a situation, it is conceivable that elevated serum calcium may be related to both an increase in exogenous intake and a decreased capacity of the skeleton to serve as a reservoir for calcium. Furthermore, in cases where relative hypoparathyroidism exists in the absence of sustained hypercalcemia, transient hypercalcemia may occur, possibly leading to poor outcomes.
In CKD, low bone turnover is associated with osteomalacia and the adynamic bone disease (ABD). Histologically, these conditions are far different from the high bone turnover associated with severe sHPT or osteitis fibrosa cystica [Malluche et al. 2004] . Osteomalacia was associated with vitamin D deficiency and exogenous aluminum intake (both as a phosphate binder as well as contamination of dialysis water), however with vitamin D replacement and a reduction in aluminum exposure, the prevalence of osteomalacia has decreased significant over the last two decades [Malluche et al. 2004] . ABD was also associated with aluminum exposure, however its prevalence has continued to increase despite the marked decrease in exposure [Malluche et al. 2004] . The persistence of the ABD may be related to over-suppression of PTH by vitamin D and calcium [Goodman et al. 1994 ] as many have speculated that uremic bone is "resistant" to PTH [Slatopolsky et al. 2000; Picton et al. 2000 ], thus requiring higher circulating levels of the hormone to maintain skeletal remodeling. The increased use of vitamin D and calcium might thus explain the persistence of the ABD. Others have suggested that CKD directly inhibits skeletal anabolism independently of PTH [Hruska et al. 2004] , and that the development of sHPT simply masks this effect. Research is currently underway to help further elucidate this process.
The association with vitamin D use and relative hypoparathyroidism or the ABD might suggest that the use of vitamin D to treat sHPT may in fact be detrimental to patients with CKD. However, the data regarding this theory appears to be to the contrary. Two recent studies involving large, diverse dialysis populations have suggested a significant survival advantage among those patients treated with vitamin D versus those not treated [Teng et al. 2005; Tentori et al. 2006 ]. Furthermore, this survival advantage extended to those patients with lower PTH levels [Tentori et al. 2006 ]. In other words, even patients with low PTH levels benefited from vitamin D therapy. Other investigators have shown that low levels of 25-OH 2 D3 and 1,25-OH 2 D3 are associated with increased arterial stiffness and endothelial dysfunction [London et al. 2007 ]. While findings suggest that vitamin D supplementation is beneficial for the vast majority of patients with advanced CKD, these conclusions are drawn from purely observational studies and not from randomized clinical trials and thus should be interpreted with caution.
Pathogenesis of poor outcomes with altered mineral metabolism
A likely link between the altered mineral metabolism and adverse clinical outcomes, particularly in regards to CVD risk, is the development of VC. VC has been described in both intimal and medial layer of arteries, as well as in the processes of calcific aortic stenosis and calcific uremic arteriolopathy (previously called calciphylaxis). In CKD, medial calcification is particularly common and results in decreased distensibility of the vessels and increased left ventricular afterload. Histologic examination of calcified vessels in humans and animals has revealed morphologic similarities to bone. Furthermore, osteoblast specific transcription factors and gene products have also been described [Tyson et al. 2003 ]. These findings suggest that vascular calcification is regulated in part by a process akin to bone formation.
It has recently been shown that vascular smooth muscle cells grown in a medium containing high concentrations of phosphorus (as phosphate) form mineralizing nodules similar to osteoblasts and express osteoblast specific transcription factors and gene products [Chen et al. 2002] . This phenotypic switch appears to involve a sodium-phosphate transporter called Pit-1. Calcium has also been shown to enhance mineralization of vascular smooth muscle cells via increased expression of Pit-1 mRNA [Yang et al.2004] . The combination of high phosphorus and high calcium concentration results in a synergistic increase in mineralization. These findings suggest that part of the poor CVD outcomes associated with hypercalcemia and hyperphosphatemia may be through the development of VC. Indeed, an elevated calcium x phosphorus product has been associated with more rapid calcification of arteries in dialysis patients [Jung et al. 2006 ].
Management of altered mineral metabolism
Control of hyperphosphatemia with dietary restriction alone is quite difficult and often requires the use of phosphate binders. In addition, despite attaining relative normophosphatemia, patients often still will develop secondary hyperparathyroidism due to vitamin D deficiency. The treatment of secondary hyperparathyroidism with active vitamin D, along with phosphate binders, has become the mainstay of therapy for patients with advanced CKD, particularly those on dialysis. However, the use of calcium based phosphate binders and vitamin D may lead to hypercalcemia. The use of noncalcium based phosphate binders such as sevelamer hydrochloride (Renagel, Genzyme Corp, Cambridge, MA, USA) and lanthanum carbonate (Fosrenol, Shire US Inc, Wayne PA, USA) have recently been introduced.
The choice of phosphate binder in the management of hyperphosphatemia is quite controversial. In the "Treat to Goal Study", 200 hemodialyis patients were randomized to sevelamer or calcium-based phosphate binders [Chertow et al. 2002] . Both groups had similar control of phosphorus, but differed in that the group treated with sevelamer had a lower incidence of hypercalcemia and "oversuppression" of PTH, improved lipid parameters, and decreased progression of VC at one year. However, this study failed to delineate how many patients were being treated with calcium carbonate and how many were treated with calcium acetate. Calcium acetate has been shown to be a more efficient phosphorus binder but contains less elemental calcium than calcium carbonate [Mai et al. 1989 ]. In the Calcium Acetate Renagel Evaluation (CARE) study, 100 hemodialysis patients were randomized to sevelamer or calcium acetate [Qunibi et al. 2004] . Investigators found that, after eight weeks of therapy, patients treated with calcium acetate had better control of phosphorus than those treated with sevelamer with less hypercalcemia. Given these results, it would have been interesting to see a direct comparison of calcium acetate with sevelamer in the "Treat to Goal" study. However, the CARE study itself has some limitations. As compared to the "Treat to Goal" study, the duration of follow-up was shorter and the dose of sevelamer was less (400 mg vs 800 mg). Neither study addressed the potential confounding effects of vitamin D.
In the Renagel in Incident Dialysis (RIND) trial [Block et al. 2005] , patients new to dialysis were randomized to calcium based binders or sevelamer. During the 18 month study period, patients without baseline VC did not progress regardless of treatment assignment while those with baseline VC progressed more rapidly with calcium based binders. Patients randomized to calcium based binders received a fairly large dose of elemental calcium (2.4 grams per day), likely secondary to the vast majority receiving calcium carbonate (90% of patients received calcium carbonate with 70% exclusively receiving this binder). Once again, a direct comparison of calcium acetate, containing less elemental calcium and perhaps better phosphate binding than calcium carbonate, with sevelamer would have been interesting. Furthermore, the lack of progression among those without baseline VC suggests that perhaps the hypothesis that increased calcium load leads to VC is not valid for all patients. A follow-up of the RIND study [Block et al. 2007 ] has suggested a survival advantage for sevelamer as compared to calcium based binders. However, after the 18 month follow-up, patients were no longer required to be maintained on their allotted treatment arm and could be treated with whatever phosphate binder their treating physician felt necessary. This could certainly confound the conclusion drawn by the authors. The post hoc mortality data from the RIND study is also different from the Dialysis Clinical Outcomes Revisited (DCOR study [Suki et al. 2007] ) where there was no difference in mortality between patients randomized to sevelamer versus calcium based binders (primarily calcium acetate). It is also possible that the beneficial effects on VC with sevelamer seen in "Treat to Goal" and RIND may be related to the lipid lowering effects of sevelamer. Preliminary results from the CARE-2 study, comparing calcium acetate and sevelamer with the addition of atorvastatin to control lipids, found no difference with binder therapy and the Review progression of VC. However, until the results of CARE-2 have been published after rigorous peer review, it is impossible to draw any definitive conclusions from this study. Despite this, we still feel that there is currently insufficient evidence to suggest that sevelamer is superior to calcium acetate.
As stated before, the use of intravenous vitamin D has been associated with improved survival among patients with end-stage renal disease [Tentori et al. 2006; Teng et al. 2005 ]. Since active vitamin D, or calcitriol, increases intestinal absorption of calcium and phosphorus, worsening of hypercalcemia or hyperphosphatemia can occur with his agent. In the United States, two less hypercalcmic vitamin D analogues have been developed: paricalcitol (Zemplar, Abbott Laboratories, Abbott Park, IL, USA) and doxercalciferol (Hectorol, Genzyme Corp, Cambridge, MA, USA). Both agents are vitamin D2 analogues as opposed to calcitriol which is the active form of vitamin D3. In two large retrospective studies examining vitamin D and mortality in dialysis patients, a significant survival advantage has been seen with the D2 analogues as compared with calcitriol [Tentori et al. 2006; Teng et al. 2003 ]. While these are not prospective, randomized, blinded trials, these findings suggest that vitamin D2 analogues should be the preferred agent to treat sHPT in CKD (at least for those who are on dialysis).
Recently, a new class of agents has been introduced in the management of sHPT. These are the calcimimetics, which act on the calcium sensing receptor in the parathyroid gland to decrease PTH secretion. These agents have shown promise, and in a retrospective analysis of 4 prospective clinical trials, the use of calcimimetics has been associated with a decreased risk of parathyroidectomy, fracture, CVD hospitalization and improved quality of life [Cunningham et al. 2005 ]. Finally, if medical management of sHPT is insufficient, parathyroidectomy is still an effective option. While some retrospective studies have suggested a survival benefit to undergoing parathyroidectomy [Kestenbaum et al. 2004] , it may be that patients undergoing parathyroidectomy were healthier and thought to be fit for surgery. It is unlikely that prospective trials will be attempted to address this issue and thus the decision to pursue parathyroidectomy should be made on an individual basis but only after aggressive medical therapy has failed.
Conclusion
CVD is extremely common in CKD and is associated with significant morbidity and mortality. The causes of increased CVD risk in CKD are complex and varied. The altered mineral metabolism of CKD likely plays a role in this setting, both directly and through its management. Strategies to improve the management of these complication are essential to help mitigate the enormous CVD burden suffered by patients with CKD.
